25-Apr-2024
AbbVie reports positive results from Rinvoq versus Dupixent study
Seeking Alpha News (Thu, 25-Apr 11:24 AM ET)
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Seeking Alpha News (Thu, 25-Apr 8:19 AM ET)
Globe Newswire (Thu, 25-Apr 7:00 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)
TipRanks (Thu, 25-Apr 5:44 AM ET)
Globe Newswire (Wed, 24-Apr 10:05 AM ET)
Globe Newswire (Mon, 22-Apr 5:54 PM ET)
Additions and deletions of Oppenheimer’s OPCO Trifecta
Seeking Alpha News (Mon, 22-Apr 3:42 PM ET)
Regeneron (REGN) Gets a Buy from Piper Sandler
TipRanks (Mon, 22-Apr 8:29 AM ET)
Globe Newswire (Thu, 18-Apr 5:03 PM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of April 25, 2024, REGN stock price declined to $890.68 with 527,492 million shares trading.
REGN has a beta of 0.59, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.13 to the broad based SPY ETF.
REGN has a market cap of $97.72 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $3 billion in Revenue and $11.86 earnings per share. This beat revenue expectation by $144 million and exceeded earnings estimates by $1.09.
In the last 3 years, REGN stock traded as high as $998.33 and as low as $478.40.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.
REGN has underperformed the market in the last year with a price return of +11.7% while the SPY ETF gained +23.6%. REGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.1% and -4.9%, respectively, while the SPY returned +4.1% and -2.1%, respectively.
REGN support price is $894.53 and resistance is $918.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN stock will trade within this expected range on the day.